Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
mSphere ; 8(1): e0060722, 2023 02 21.
Article in English | MEDLINE | ID: covidwho-2263909
2.
J Virol ; 97(2): e0008923, 2023 02 28.
Article in English | MEDLINE | ID: covidwho-2223569

ABSTRACT

Viruses have brought humanity many challenges: respiratory infection, cancer, neurological impairment and immunosuppression to name a few. Virology research over the last 60+ years has responded to reduce this disease burden with vaccines and antivirals. Despite this long history, the COVID-19 pandemic has brought unprecedented attention to the field of virology. Some of this attention is focused on concern about the safe conduct of research with human pathogens. A small but vocal group of individuals has seized upon these concerns - conflating legitimate questions about safely conducting virus-related research with uncertainties over the origins of SARS-CoV-2. The result has fueled public confusion and, in many instances, ill-informed condemnation of virology. With this article, we seek to promote a return to rational discourse. We explain the use of gain-of-function approaches in science, discuss the possible origins of SARS-CoV-2 and outline current regulatory structures that provide oversight for virological research in the United States. By offering our expertise, we - a broad group of working virologists - seek to aid policy makers in navigating these controversial issues. Balanced, evidence-based discourse is essential to addressing public concern while maintaining and expanding much-needed research in virology.


Subject(s)
Research , Virology , Virus Diseases , Humans , COVID-19/prevention & control , Information Dissemination , Pandemics/prevention & control , Policy Making , Research/standards , Research/trends , SARS-CoV-2 , Virology/standards , Virology/trends , Virus Diseases/prevention & control , Virus Diseases/virology , Viruses
3.
J Nanobiotechnology ; 20(1): 41, 2022 Jan 21.
Article in English | MEDLINE | ID: covidwho-1643157

ABSTRACT

Early detection of viral pathogens by DNA-sensors in clinical samples, contaminated foods, soil or water can dramatically improve clinical outcomes and reduce the socioeconomic impact of diseases such as COVID-19. Clustered regularly interspaced short palindromic repeat (CRISPR) and its associated protein Cas12a (previously known as CRISPR-Cpf1) technology is an innovative new-generation genomic engineering tool, also known as 'genetic scissors', that has demonstrated the accuracy and has recently been effectively applied as appropriate (E-CRISPR) DNA-sensor to detect the nucleic acid of interest. The CRISPR-Cas12a from Prevotella and Francisella 1 are guided by a short CRISPR RNA (gRNA). The unique simultaneous cis- and trans- DNA cleavage after target sequence recognition at the PAM site, sticky-end (5-7 bp) employment, and ssDNA/dsDNA hybrid cleavage strategies to manipulate the attractive nature of CRISPR-Cas12a are reviewed. DNA-sensors based on the CRISPR-Cas12a technology for rapid, robust, sensitive, inexpensive, and selective detection of virus DNA without additional sample purification, amplification, fluorescent-agent- and/or quencher-labeling are relevant and becoming increasingly important in industrial and medical applications. In addition, CRISPR-Cas12a system shows great potential in the field of E-CRISPR-based bioassay research technologies. Therefore, we are highlighting insights in this research direction.


Subject(s)
CRISPR-Cas Systems/physiology , DNA, Viral/isolation & purification , Nucleic Acid Amplification Techniques , Animals , Biosensing Techniques/methods , Biosensing Techniques/trends , COVID-19/virology , DNA, Viral/analysis , Environmental Pollutants/analysis , Environmental Pollutants/isolation & purification , Food Contamination/analysis , Humans , Molecular Typing/methods , Molecular Typing/trends , Nucleic Acid Amplification Techniques/methods , Nucleic Acid Amplification Techniques/trends , SARS-CoV-2/genetics , Virology/methods , Virology/trends , Virus Diseases/classification , Virus Diseases/diagnosis , Virus Diseases/virology
6.
Viral Immunol ; 33(7): 493, 2020 09.
Article in English | MEDLINE | ID: covidwho-798544
7.
Biologicals ; 66: 35-40, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-612146

ABSTRACT

This first International Alliance for Biological Standardization Covid-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable delegation from low- and middle-income countries, to discuss the virology, epidemiology and immunology of, and the vaccine development for SARS-CoV-2.


Subject(s)
Betacoronavirus , Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , Viral Vaccines , Adult , Aged , Aged, 80 and over , Basic Reproduction Number , COVID-19 , COVID-19 Vaccines , Congresses as Topic , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Drug Design , Female , Global Health , Humans , International Cooperation , Internet , Male , Middle Aged , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Reference Standards , SARS-CoV-2 , Seasons , Telecommunications , Virology/trends , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL